Recruiting Amyloidosis Studies in Kansas City
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
This is an open-label, multi-center pivotal Phase 3 study to visually and quantitatively assess PET images obtained after single application of 300 MBq \[18F\]florbetaben and PET scanning of patients ...
A Study of AT-02 in Subjects With Systemic Amyloidosis.
This is a Phase 2 open-label extension study to evaluate the long-term safety, tolerability, and clinical activity of AT-02. AT-02 is an investigational medicinal product being developed to treat sys...
About Amyloidosis Clinical Trials in Kansas City
Amyloidosis is a group of diseases in which abnormal proteins (amyloids) build up in organs and tissues, impairing their function. Types include AL, AA, and ATTR amyloidosis. Treatment depends on the type and may include chemotherapy, organ transplant, or targeted therapies.
There are currently 2 amyloidosis clinical trials recruiting participants in Kansas City, KANSAS. These studies are seeking a combined 320 participants. Research is being sponsored by Life Molecular Imaging GmbH, Attralus, Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.
Amyloidosis Clinical Trials in Kansas City — FAQ
Are there amyloidosis clinical trials in Kansas City?
Yes, there are 2 amyloidosis clinical trials currently recruiting in Kansas City, KANSAS. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Kansas City?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Kansas City research site will contact you about next steps.
Are clinical trials in Kansas City free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Kansas City studies also compensate for your time and travel.
What amyloidosis treatments are being tested?
The 2 active trials in Kansas City are testing new therapies including novel drugs, biologics, and treatment approaches for amyloidosis.
Data updated March 2, 2026 from ClinicalTrials.gov